Safety, efficacy and lessons from continuous infusion with rFVIIa Conferences

abstract

• Summary. Continuous infusion with coagulation factor concentrates has only been widely adopted during the last decade and with recombinant activated factor VII (rFVIIa) only during the last 2 years. Still the accumulated number of days on continuous infusion with this product amounts by now to more than one year, 35 patients and 26 surgical procedures. The experience is reviewed here and compared with data from the conventional bolus dose regimen.

authors

• Lee, CA
• Kessler, CM
• Varon, D
• Martinowitz, U
• Heim, M
• Schulman, Sam

status

• published 

publication date

• July 1998

has subject area

• 1103 Clinical Sciences (FoR)
• Cardiovascular System & Hematology (Science Metrix)
• Factor VIIa (MeSH)
• Hemophilia A (MeSH)
• Humans (MeSH)
• Infusions, Intravenous (MeSH)
• Recombinant Proteins (MeSH)
• Time Factors (MeSH)

published in

• Haemophilia  Journal

presented at event

• XXIII International Congress of the World-Federation-of-Hemophilia  Conference

keywords

• Hematology
• INHIBITORS
• Life Sciences & Biomedicine
• NOVOSEVEN(R)
• RECOMBINANT FACTOR-VIIA
• Science & Technology
• activated factor VII
• continuous infusion
• haemophilia
• inhibitor

Digital Object Identifier (DOI)

• 10.1046/j.1365-2516.1998.440564.x

PubMed ID

• 9873795

start page

• 564

end page

• 567

volume

• 4

issue

• 4